Celyad Oncology SA
XBRU:CYAD

Watchlist Manager
Celyad Oncology SA Logo
Celyad Oncology SA
XBRU:CYAD
Watchlist
Price: 0.4745 EUR -5.1%
Market Cap: 19.7m EUR
Have any thoughts about
Celyad Oncology SA?
Write Note

EV/OCF
Enterprise Value to OCF

-1.4
Current
-0.6
Median
6
Industry
Lower than median
Lower than industry value

Enterprise Value to Operating Cash Flow (EV/OCF) ratio is a valuation multiple that measures the value of a company, debt included, to the operating cash flow it generates.

EV/OCF
-1.4
=
Enterprise Value
13.6m EUR
/
Operating Cash Flow
-9.7m EUR
All Countries
Close
Market Cap EV/OCF
BE
Celyad Oncology SA
XBRU:CYAD
19.7m EUR -1.4
FR
Pharnext SCA
OTC:PNEXF
6T USD -236 051.4
US
Abbvie Inc
NYSE:ABBV
300.2B USD 21.3
US
Amgen Inc
NASDAQ:AMGN
159.1B USD 28.5
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
126.6B USD -127.3
US
Gilead Sciences Inc
NASDAQ:GILD
114.6B USD 10.9
US
Epizyme Inc
F:EPE
94.1B EUR -477
AU
CSL Ltd
ASX:CSL
137.3B AUD 35.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
87.6B USD 19
US
Seagen Inc
F:SGT
39.3B EUR -74.6
NL
argenx SE
XBRU:ARGX
34.1B EUR -126.8
 
BE
Celyad Oncology SA
XBRU:CYAD
Average EV/OCF: 23.1
Negative Multiple: -1.4
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -236 051.4
US
Abbvie Inc
NYSE:ABBV
21.3
US
Amgen Inc
NASDAQ:AMGN
28.5
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -127.3
US
Gilead Sciences Inc
NASDAQ:GILD
10.9
US
E
Epizyme Inc
F:EPE
Negative Multiple: -477
AU
CSL Ltd
ASX:CSL
35.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
19
US
S
Seagen Inc
F:SGT
Negative Multiple: -74.6
NL
argenx SE
XBRU:ARGX
Negative Multiple: -126.8

EV/OCF Forward Multiples

Forward EV/OCF multiple is a version of the EV/OCF ratio that uses forecasted operating cash flow for the EV/OCF calculation. 1-Year, 2-Years, and 3-Years forwards use operating cash flow forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/OCF
N/A
2-Years Forward
EV/OCF
N/A
3-Years Forward
EV/OCF
N/A

See Also

Discover More